Keros Therapeutics, Inc. (KROS) Stock

Keros Therapeutics, Inc. (KROS) is a Healthcare stock trading at $11.06 (as of 2026-08-21), with a market capitalization of $219.29M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing and commercializing treatments for patients with hematological and musculoskeletal disorders. Its lead candidate KER-050 targets cytopenias in myelodysplastic syndromes and myelofibrosis, while KER-047 is in Phase 1 for anemia and KER-012 is in Phase 1 for disorders associated with bone loss and pulmonary arterial hypertension.

Understand Keros Therapeutics, Inc.: how it makes money

Keros Therapeutics is a clinical-stage biopharmaceutical company that discovers, develops, and aims to commercialize novel treatments for hematological and musculoskeletal disorders, with lead programs KER-050 (cytopenias in myelodysplastic syndromes and myelofibrosis) and KER-047, and it currently reports service and other revenue.

Because KER-050 and KER-047 are still being developed, the path to a stronger profit profile depends on turning these development programs into commercialization, while the latest reported revenue comes only from service and other revenue (0.0 in the period).

Revenue by segment (latest quarter)
Service & other$0.0B

Business quality (Weak): The company is clinical-stage and the latest period shows 0.0 revenue and a very large negative operating margin, so investor visibility into the profit model is limited until product progress translates into meaningful commercial revenue.

Bull case

  • Clear clinical-stage focus on defined programs: The company’s lead therapeutic candidate is KER-050 for cytopenias (including anemia and thrombocytopenia) in myelodysplastic syndromes and in myelofibrosis, and it is also developing KER-047.
  • Defined revenue line item reported: The latest reported revenue is categorized as service and other revenue, which helps track any non-program revenue activity over time.

Bear case

  • No revenue generated in the latest reported period: Total revenue is 0.0B for the period ending 2026-03-31, with service and other revenue also at 0.0B.
  • Material operating losses: Operating margin is reported as -80865.6 for the period ending 2026-03-31, indicating substantial losses.
Valuation — source: SEC EDGAR (first-party)
Price$11.06
Market Cap$219.29M
Price / Book0.84
Price / Sales15.46
FCF Yield-14.3%
DCF Value (model)$234.92
DCF Upside vs Price2024.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$243.86M
Net Margin35.7%
Revenue Growth (YoY)6769.4%
EPS Growth (YoY)-146.8%
FCF Growth (YoY)-165.1%
Financial Health — source: SEC EDGAR
Altman Z-Score4.18 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($31.06M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJasbir S. Seehra
Employees163
CountryUS
IPO Date2020-04-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Organogenesis Holdings Inc. (ORGO)
  • Minerva Neurosciences, Inc. (NERV)
  • Avidity Biosciences, Inc. (RNA)
  • Immunic, Inc. (IMUX)
  • AN2 Therapeutics, Inc. (ANTX)
  • SIGA Technologies, Inc. (SIGA)
  • PepGen Inc. (PEPG)
  • Journey Medical Corporation (DERM)
KROS earnings history · KROS institutional & insider holders · KROS KPIs & operating metrics · KROS financials · KROS investor presentations & press releases · KROS SEC filings · KROS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.